Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$628M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$567M |
| 3 |
Biogen
BIIB
|
+$405M |
| 4 |
UnitedHealth
UNH
|
+$392M |
| 5 |
Walmart Inc
WMT
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$451M |
| 2 |
PepsiCo
PEP
|
+$382M |
| 3 |
Philip Morris
PM
|
+$256M |
| 4 |
Roku
ROKU
|
+$252M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.91% |
| 2 | Technology | 12.35% |
| 3 | Consumer Discretionary | 10.31% |
| 4 | Financials | 9.99% |
| 5 | Consumer Staples | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Eldorado Gold
EGO
$10B
| $46.5M | 0.04% |
5,992,069
+2,391,536
| +66% | +$19.4M |
|
|
ATRI
527
DELISTED
Atrion Corp
ATRI
| $46.5M | 0.04% |
59,700
-1,200
| -2% | -$931K |
|
528
Stride
LRN
$3.48B
| $46.5M | 0.04% |
1,761,300
+128,000
| +8% | +$3.68M |
|
|
FLG
529
Flagstar Bank National Association
FLG
$5.92B
| $46.4M | 0.04% |
1,233,475
+257,933
| +26% | +$8.89M |
|
530
Mercado Libre
MELI
$92.7B
| $46.3M | 0.04% |
84,000
-25,100
| -23% | -$15.2M |
|
531
PVH
PVH
$3.77B
| $46.3M | 0.04% |
524,675
-655,800
| -56% | -$54.8M |
|
532
Pacira BioSciences
PCRX
$924M
| $46.3M | 0.04% |
1,215,100
+122,900
| +11% | +$4.91M |
|
|
LMNX
533
DELISTED
Luminex Corp
LMNX
| $45.9M | 0.04% |
2,220,742
-71,900
| -3% | -$1.5M |
|
534
Cracker Barrel
CBRL
$1.31B
| $45.8M | 0.04% |
281,632
+206,149
| +273% | +$34.7M |
|
535
Sumitomo Mitsui Financial
SMFG
$167B
| $45.7M | 0.04% |
6,684,115
+2,402,215
| +56% | +$16.4M |
|
|
Y
536
DELISTED
Alleghany Corp
Y
| $45.7M | 0.04% |
57,288
-17,500
| -23% | -$12.9M |
|
|
CLGX
537
DELISTED
Corelogic, Inc.
CLGX
| $45.7M | 0.04% |
987,200
+327,900
| +50% | +$15.1M |
|
538
Lloyds Banking Group
LYG
$90B
| $45.5M | 0.04% |
17,216,300
+788,200
| +5% | +$2.04M |
|
539
Flex
FLEX
$45.9B
| $45.4M | 0.04% |
5,755,801
-492,848
| -8% | -$3.79M |
|
540
Kite Realty
KRG
$5.31B
| $45.1M | 0.04% |
2,790,900
+315,700
| +13% | +$4.84M |
|
541
VF Corp
VFC
$5.79B
| $45M | 0.04% |
505,390
+299,890
| +146% | +$25.6M |
|
|
ENDP
542
DELISTED
Endo International plc
ENDP
| $44.9M | 0.04% |
13,990,000
+2,283,800
| +20% | +$7.36M |
|
543
Pricesmart
PSMT
$5.55B
| $44.9M | 0.04% |
631,500
+71,100
| +13% | +$4.31M |
|
|
DFS
544
DELISTED
Discover Financial Services
DFS
| $44.9M | 0.04% |
553,600
+397,200
| +254% | +$32.8M |
|
545
Regis Corp
RGS
$70.1M
| $44.5M | 0.04% |
110,090
+2,800
| +3% | +$1.01M |
|
546
Diageo
DEO
$52.8B
| $44.4M | 0.04% |
271,700
+109,199
| +67% | +$18.3M |
|
|
SRDX
547
DELISTED
Surmodics
SRDX
| $44.3M | 0.04% |
969,538
-81,000
| -8% | -$3.53M |
|
|
EQC
548
DELISTED
Equity Commonwealth
EQC
| $44.3M | 0.04% |
1,294,160
-371,605
| -22% | -$12.5M |
|
|
TSE
549
DELISTED
Trinseo
TSE
| $43.9M | 0.04% |
1,022,400
+9,500
| +0.9% | +$354K |
|
|
TARO
550
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $43.9M | 0.04% |
581,700
+28,736
| +5% | +$2.33M |
|
Similar funds
Jim Simons's Q3 2019 Portfolio in Review
As of Q3 2019, Jim Simons held 3,920 positions worth $118B, up 4% from $114B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons deployed $5.29B of net new capital in Q3 2019, opening 406 new positions and adding to 1,848 existing holdings. Its largest new stake was UnitedHealth: 1,624,826 shares worth $353M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $451M trimmed.
- Jim Simons's largest Q3 2019 buy was UnitedHealth: 1,624,826 shares worth $353M.
- Jim Simons added most to Celgene Corp in Q3 2019, an estimated $628M increase.
- Jim Simons's biggest Q3 2019 reduction was Apple, cutting an estimated $451M.
- Jim Simons fully exited Red Hat Inc in Q3 2019, selling an estimated $248M.
- Jim Simons's ten largest holdings make up 11% of its $118B portfolio in Q3 2019.
- Jim Simons opened 406 new positions and closed 522 in Q3 2019.
- Jim Simons's portfolio value rose 4% quarter-over-quarter to $118B.
Based on Renaissance Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.